Innovitro Overview

  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $7.58K
Latest Deal Amount
  • Investors
  • 2

Innovitro General Information

Description

Provider of cell-based allergy tests. The company focuses on providing animal free way of determining the sensitizing potency of chemicals based on the response of skin cell lines to exposure to the chemicals.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Primary Office
  • Erik Dahlbergsgatan 11A
  • 2nd Floor
  • SE-411 26 Gothenburg
  • Sweden
+46 070-713 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Innovitro Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 01-Jan-2013 $7.58K 00.000 Completed Startup
1. Accelerator/Incubator 01-Jan-2009 00.000 00.000 Completed Startup
To view Innovitro’s complete valuation and funding history, request access »

Innovitro Executive Team (2)

Name Title Board Seat Contact Info
Jenny Almkvist Ph.D Project Manager
You’re viewing 1 of 2 executive team members. Get the full list »

Innovitro Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Swedish Fund for Research without Animal Experiments Other 000 0000 000000 0
GU Ventures Accelerator/Incubator Minority 000 0000 000000 0
To view Innovitro’s complete investors history, request access »